A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both?
Free accessReview articleFirst published online December, 2006
A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both?
Growth hormone plays an integral role in the development and maintenance of structure and function of the heart. Specific involvement of the heart in acromegaly is termed acromegalic cardiomyopathy, manifested as concentric left ventricular hypertrophy and diastolic dys-function. Left untreated, it ultimately progresses to systolic heart failure. Heart failure from acromegalic cardiomyopathy is one of the most common causes of death in acromegaly. Current treatment options include different approaches to lower elevated growth hormone levels with improvement in symptoms, exercise tolerance, and echocardiographic improvement in regression of left ventricular hypertrophy and indices of diastolic dysfunction. On the other hand, growth hormone is essential for cardiac growth and function and exerts beneficial and protective effects on the cardiovascular system. Its potential role as adjunctive therapy in the treatment of heart failure as derived from experimental studies and clinical trials is discussed.
Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency in adults. Clin Endocrinol. 1992;37:387-397.
2.
De Boer H, Blok GJ, Van der Veen E. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995; 16:63-86.
3.
Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res. 1995;30:825-834.
4.
Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-335.
5.
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol. 1994;41:95-102.
6.
Orme SM, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998; 83:2730-2734.
7.
Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin like growth factor I levels on cardiac performance. J Clin Endocrinol Metab. 2001;86:1551-1557.
8.
Lopez-Velasco R, Escobar-Morreale H, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab. 1997;82:1047-1053.
9.
Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P. A hyperkinetic heart in uncomplicated acromegaly: explanation of hypertension in acromegalic patients?Acta Med Scand. 1988;223:337-343.
10.
Bruch C, Herrmann B, Schmermund A, Bartel T, Mann K, Erbel R. Impact of disease activity on left ventricular performance in patients with acromegaly. Am Heart J. 2002;144:538-543.
11.
Jaffrain-Rea ML, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol. 2003; 148:193-201.
12.
Baldelli R, Ferretti E, Jaffrain-Rea M, et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab. 1999;84:527-532.
13.
Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262-267.
14.
Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab. 1993;77:1671-1676.
15.
Frustaci A, Perrone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol. 1992;97:503-511.
16.
Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
17.
Volterrani M, Desenzani P, Lorusso R, d'Aloia A, Manelli F, Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet. 1997;349:1067-1068.
18.
Genth-Zotz S, Zotz R, Geil S, Voigtlander T, Meyer J, Darius H. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation. 1999;99:18-21.
19.
Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998;19:1704-1711.
20.
Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.
21.
Osterziel KJ, Ranke MB, Strohm O, Dietz R. The soma-totrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol. 2000;53:61-68.
22.
Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38:443-452.
23.
Ibe W, Saraste A, Lindemann S, et al. Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment. Eur J Heart Fail. Epub ahead of print August 3, 2006.
24.
Mital S, Andron A, Lamour JM, Hsu DT, Addonizio LJ, Softness B. Effects of growth hormone therapy in children after cardiac transplantation. J Heart Lung Transplant. 2006;25:772-777.
25.
Engelmann GL, Boehm KD, Haskell JF, Khairallah PA, Liana J. Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol. 1989;63:1-14.
Donath MY, Jenni R, Brunner HP, et al. Cardiovascular and metabolic effects of insulin-like growth factor-I at rest and during exercise in humans. J Clin Endocr Metab. 1996;81:4089-4094.
28.
Bisi G, Podio V, Valetto MR, et al. Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. Eur J Endocrinol. 1999;140:322-327.
29.
Yoshioka S, Takahashi Y, Okimura Y, et al. Gene expression profile in the heart of spontaneous dwarf rat: in vivo effects of growth hormone. Biochem Biophys Res Commun. 2006;341:88-93.
30.
Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674-3679.
31.
Nagaya N, Kangawa K. Therapeutic potential of ghrelin in the treatment of heart failure. Drugs. 2006;66:439-448.
32.
Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. J Am Coll Cardiol. 2006;48:1111-1119.
33.
Napoli R. Growth hormone, vascular reactivity, and heart failure. Eur J Clin Pharmacol. 2006;62(suppl 13):141-144.
34.
Sacca L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intircate triangulation. Clin Endocrinol. 59;2003:660-671.
35.
Bocchi E, Moura L, Guimaraes G, Conceicao Souza GE, Ramires JA. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol. 2006;110:313-317.
36.
Colao A, Di Somma C, Vitale G, Filippella M, Lombardi G. Influence of growth hormone on cardiovascular health and disease. Treat Endocrinol. 2003;2: 347-356.
37.
Pedersen HD, Falk T, Haggstrom J, et al. Circulating concentrations of insulin-like growth factor-1 in dogs with naturally occurring mitral regurgitation. J Vet Intern Med. 2005;19:528-532.
38.
Xu XB, Pang JJ, Cao JM, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H1643-H1651.
39.
Parissis JT, Adamopoulos S, Karatzas D, Paraskevaidis J, Livanis E, Kremastinos D. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur J Cardiovasc Prev Rehabil. 2005;12:164-168.
40.
Mitsi AC, Hatzistergos K, Baltogiannis GG, Kolettis TM. Early, selective growth hormone administration may ameliorate left ventricular remodeling after myocardial infarction. Med Hypotheses. 2005;64:582-585.
41.
Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004;151(suppl 1):S93-S101.
42.
Iglesias MJ, Pineiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62:481-488.
43.
Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777-2781.
44.
Migliaretti G, Aimaretti G, Borraccino A, et al. Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: data from the GH Registry. J Endocrinol Invest. 2006; 29:438-442.
45.
McGuffin WL Jr, Sherman BM, Roth J, et al. Acromegaly and cardiovascular disorders: a prospective study. Ann Intern Med. 1974;81:11-18.
46.
Smallridge RC, Rajfer S, Davia J, Schaaf M. Acromegaly and the heart: an echocardiographic study. Am J Med. 1979;66:22-27.
47.
Fazio S, Cittadini A, Sabatini D, et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J. 1993;14:26-33.
48.
Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555-573.
49.
Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980;100:41-52.
50.
Savage DD, Henry WL, Eastman RC, Borer JF, Gorden P. Echocardiographic assessment of cardiac anatomy and function in acromegalic patients. Am J Med. 1979;57:823-829.
51.
Minniti G, Jaffrain-Rea ML, Moroni C, et al. Echocardio-graphic evidence for a direct effect of GH/IGF-I hyper-secretion on cardiac mass and function in young acromegalics. Clin Endocrinol. 1998;49:101-106.
52.
Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-term growth hormone secretion. J Clin Endocrinol. 2000;85:179-182.
53.
Ohtsuka G, Aomi S, Koyanagi H, et al. Heart valve operation in acromegaly. Ann Thorac Surg. 1997;64:390-393.
54.
Frustaci A, Chementi C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation. 1999;23:1426-1434.
55.
Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol. 2001;54:137-154.
56.
Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000;85:193-199.
57.
Herrmann BL, Bruch C, Saller B, et al. Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy. Clin Endocrinol. 2002;56:595-602.
58.
Coalo A, Cuocolo A, Marzullo P, et al. Impact of a patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab. 1999;84:1518-1523.
59.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-152.
60.
Chanson P, Megnien JL, del Pino M, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol. 1998;49:725-731.
61.
Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol. 2000;53:445-451.
62.
Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87:3174-3179.
63.
Schiavon F, Maffei P, Martini C, et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab. 1999;84:3151-3155.
64.
Colao A, Spiezia S, Cerbone G, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultra-sonography in acromegaly. Clin Endocrinol. 2001;54: 515-524.
65.
Otsuki M, Kasayama S, Yamamoto H, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol. 2001;54:791-796.
66.
Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol. 1998;48:149-152.
67.
Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4:239-249.
68.
Terzolo M, Matrella C, Boccuzzi A, et al. Twenty-four-hour profile of blood pressure in patients with acromegaly: correlation with demographic, clinical and hormonal features. J Endocrinol Invest. 1999;22:48-54.
69.
Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res. 1991;36:44-48.
McKnight JA, McCance DR, Hadden DR, et al. Basal and saline stimulated levels of plasma atrial natriuretic peptide factor in acromegaly. Clin Endocrinol. 1989;31: 431-438.
72.
Moller J, Jorgensen JOL, Moller N, Hansen KW, Pedersen EB, Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab. 1991;72:768-772.
73.
Ikeda T, Terasawa H, Ishimura M, et al. Correlation between blood pressure and plasma insulin in acromegaly. J Intern Med. 1993;234:61-63.
74.
Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, degli Uberti EC. Diurnal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metab. 1999;84:2458-2467.
75.
Wickman A, Friberg P, Adams MA, et al. Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Hypertension. 1997;29:123-130.
76.
Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res. 2001;34:1429-1433.
77.
Muggeo M, Saviolakis GA, Businaro V, Valerio A, Moghetti P, Crepaldi G. Insulin receptor on monocytes from patients with acromegaly and fasting hyperglycemia. J Clin Endocrinol Metab. 1983;56:733-738.
78.
Rosenfeld RG, Wilson DM, Dollar LA, Bennett A, Hintz RL. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab. 1982;54:1033-1038.
79.
Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab. 2002;87:3097-3104.
80.
Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24:272-277.
81.
Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med. 2002;112:610-616.
82.
Hayward RP, Emanuel RW, Nabarro JD. Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med. 1987;62:41-58.
83.
Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13:51-56.
84.
Mohamed AL, Yusoff K, Muttalif AR, Khalid BA. Markers of ventricular tachyarrythmias in patients with acromegaly. Med J Malaysia. 1999;54:338-345.
85.
Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998; 89:353-358.
86.
Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-3426.
87.
Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab. 1997;82:3308-3314.
88.
Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol. 2001;55:307-313.
89.
Baldwin A, Cundy T, Butler J, Timmis AD. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta Endocrinol. 1985; 108:26-30.
90.
Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab. 2000;85:3779-3785.
91.
Jackson IM, Noren G. Role of Gamma Knife radio-surgery in acromegaly. Pituitary. 1999;2:71-77.
92.
Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992;21:713-735.
93.
Racine MS, Barkan AL. Medical management of growth hormone-secreting pituitary adenomas. Pituitary. 2002; 5:67-76.
94.
Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83:374-378.
95.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246-254.
96.
Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P. The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol. 1989;30:619-625.
97.
Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 1990;113:921-925.
98.
Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab. 1993;77:790-793.
99.
Tokgözoglu SL, Erbaş T, Aytemir K, Akalin S, Kes S, Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol. 1994;74:1072-1074.
100.
Giustina A, Boni E, Romanelli G, Grassi V, Giustina G. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol. 1995;75:1042-1047.
101.
Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab. 1999;84:17-23.
102.
Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow release somatostatin analog). Am J Cardiol. 1999; 83:1506-1509.
103.
Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85:3132-3140.
104.
Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol. 2003;58:169-176.
105.
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
106.
Liang C, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation. 1984; 89:113-119.
107.
Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol. 1997;80:61-64.
108.
Abraham WT, Fisher WG, Smith AL, et al, MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
109.
Chanson P, Timsit J, Masquet C, Guillausseau PJ, Warnet A, Lubetzki J. Heart failure responding to octreotide in patient with acromegaly. Lancet. 1989;1: 1263-1264.
110.
Legrand V, Beckers A, Pham VT, Demoulin JC, Stevenaert A. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery. Eur Heart J. 1994;15:1286-1289.
111.
Nishiki M, Murakami Y, Sohmiya M, et al. Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide. Endocr J. 1997;44:655-660.
112.
Shimakura A, Miyakoshi H, Ohkuwa H, et al. Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure. Jpn Heart J. 2002;43:69-77.
113.
Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004; 89:5308-5313.
